Venlafaxine or a second SSRI: Switching after treatment failure with an SSRI among depressed inpatients: A retrospective analysis

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 7, 2011, Pages 1744-1747

  Barak, Yoram ^a   Swartz, Marnina ^b   Baruch, Yehuda ^a  

^a ABARBANEL MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Depression; Inpatients; SSRI; Venlafaxine

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; AGED; ARTICLE; CGI S SCORE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG TREATMENT FAILURE; DYSLIPIDEMIA; FEMALE; HOSPITAL PATIENT; HUMAN; HYPERTENSION; ISRAEL; LENGTH OF STAY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; RETROSPECTIVE STUDY; SCORING SYSTEM; TERTIARY HEALTH CARE; TREATMENT DURATION; UNIVERSITY HOSPITAL; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; CHRONIC DISEASE; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; INPATIENTS; ISRAEL; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, ADRENERGIC; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SUICIDE, ATTEMPTED; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79961126439     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.06.007     Document Type: Article

References (19)

1. Ackerman D.L., Unützer J., Greenland S., Gitlin M. Inpatient treatment of depression and associated hospital charges. Pharmacoepidemiol Drug Saf 2002, 11:219-227.
2. Bandelow B., Baldwin D.S., Dolberg O.T., Andersen H.F., Stein D.J. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?. J Clin Psychiatry 2006, 67:1428-1434.
3. Bauer M., Monz B.U., Montejo A.L., Quail D., Dantchev N., Demyttenaere K., et al. Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study. Eur Psychiatry 2008, 23:66-73.
4. Bauer M., Pfennig A., Linden M., Smolka M.N., Neu P., Adli M. Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression. J Clin Psychopharmacol 2009, 29:327-333.
5. Birkenhäger T.K., van den Broek W.W., Moleman P., Bruijn J.A. Outcome of a 4-step treatment algorithm for depressed inpatients. J Clin Psychiatry 2006, 67:1266-1271.
6. Cheng I.C., Liao S.C., Lee M.B., Tseng M.M. Predictors of treatment response and length of stay for inpatients with major depression. J Formos Med Assoc 2007, 106:903-910.
7. Dorz S., Borgherini G., Conforti D., Scarso C., Magni G. Depression in inpatients: bipolar vs unipolar. Psychol Rep 2003, 92:1031-1039.
8. Guy W. ECDEU assessment manual for psychopharmacology. Biometric laboratory. The George Washington University, Department of Health, Education, and Welfare-DHEW 1976, 218-222. Publication No. (ADM), Kensington, MD, US.
9. Hennings J.M., Owashi T., Binder E.B., Horstmann S., Menke A., Kloiber S., et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients-findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 2009, 43:215-229.
10. Insel T.R., Wang P.S. The STAR*D trial: revealing the need for better treatments. Psychiatr Serv 2009, 60:1466-1467.
11. Kaltiala-Heino R., Laippala P., Joukamaa M. Inpatient treatment of mood disorders in the era of de-institutionalisation, depression awareness campaigns and development of new antidepressants. J Affect Disord 2003, 76:31-37.
12. Kennedy S.H., Andersen H.F., Thase M.E. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin 2009, 25:161-175.
13. Lenox-Smith A.J., Jiang Q. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Int Clin Psychopharmacol 2008, 23:113-119.
14. Mazeh D., Shahal B., Aviv A., Zemishlani H., Barak Y. A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression. Int Clin Psychopharmacol 2007, 22:371-375.
15. Montgomery S.A., Baldwin D.S., Blier P., Fineberg N.A., Kasper S., Lader M., et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 2007, 22:323-329.
16. SAS Institute SAS/STAT Users' Guide, Version 6, 4th edn, vols. 1 and 2. Cary, NC 1990, SAS Institute.
17. Seemüller F., Riedel M., Obermeier M., Bauer M., Adli M., Kronmüller K., et al. Outcomes of 1014 naturalistically treated inpatients with major depressive episode. Eur Neuropsychopharmacol 2010, 20:346-355.
18. Sim K., Lee N.B., Chua H.C., Mahendran R., Fujii S., Yang S.Y., et al. Newer antidepressant drug use in East Asian psychiatric treatment settings: REAP (Research on East Asia Psychotropic Prescriptions) study. Br J Clin Pharmacol 2007, 63:431-437.
19. Tseng M.C., Cheng I.C., Lee Y.J., Lee M.B. Intermediate-term outcome of psychiatric inpatients with major depression. J Formos Med Assoc 2006, 105:645-652.